{"id":"ceftriaxone-v-penicillin-and-gentamicin","rwe":[],"tags":[],"safety":{"boxedWarnings":["Hypersensitivity reactions, including anaphylaxis, may occur."],"drugInteractions":["Warfarin: Increased risk of bleeding","Probenecid: Increased serum levels of ceftriaxone","Aminoglycosides: Increased risk of nephrotoxicity"],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"10%","severity":"Mild"},{"effect":"Nausea","drugRate":"5%","severity":"Mild"},{"effect":"Rash","drugRate":"3%","severity":"Mild"},{"effect":"Vomiting","drugRate":"2%","severity":"Mild"},{"effect":"Injection site pain","drugRate":"2%","severity":"Mild"}],"contraindications":["Known hypersensitivity to ceftriaxone or other cephalosporins","History of severe allergic reactions to penicillins"],"specialPopulations":{"Lactation":"Ceftriaxone is excreted in breast milk; monitor infant for adverse effects.","Pregnancy":"Category B: No evidence of harm in animal studies; no well-controlled human studies.","Renal Impairment":"Dose adjustment may be necessary.","Hepatic Impairment":"No dose adjustment is required."}},"trials":[],"_chembl":{"chemblId":"CHEMBL1200852","moleculeType":"Small molecule","molecularWeight":"388.49"},"aliases":[],"patents":[{"title":"7-Aminocephalosporanic acid derivatives and their preparation","number":"US4326009A","issueDate":"1982-04-20","expirationDate":"2002-04-20"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$2.1649/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$790","description":"CEFTRIAXONE 1 GM VIAL","retrievedDate":"2026-04-07"}],"offLabel":[],"timeline":[{"date":"1984","type":"Approval","milestone":"First approved by the FDA","regulator":"FDA"}],"_dailymed":null,"aiSummary":"Ceftriaxone is a third-generation cephalosporin antibiotic used to treat a wide range of bacterial infections. It is often compared to penicillin and gentamicin due to its broad-spectrum activity and favorable pharmacokinetic properties. Unlike penicillin, ceftriaxone has a longer half-life and can be administered less frequently. Compared to gentamicin, ceftriaxone has a lower risk of nephrotoxicity and ototoxicity. However, it is important to note that ceftriaxone should not be used in patients with a history of severe allergic reactions to cephalosporins or penicillins.","ecosystem":[],"mechanism":{"target":"Penicillin-binding proteins (PBPs)","novelty":"Ceftriaxone was introduced as an improvement over earlier cephalosporins, offering broader spectrum activity and better pharmacokinetic properties.","modality":"Antibacterial","drugClass":"Third-generation cephalosporin","explanation":"Ceftriaxone works by interfering with the synthesis of the bacterial cell wall, leading to cell lysis and death.","oneSentence":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs).","technicalDetail":"Ceftriaxone binds to PBPs, which are enzymes involved in the cross-linking of peptidoglycan chains, essential for maintaining the structural integrity of the bacterial cell wall."},"_scrapedAt":"2026-03-28T00:29:50.231Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"Not available","launchDate":"Not available","annualCostUS":"Not available","currentRevenue":"Not available","patientPopulation":"Broad, including hospitalized patients and outpatients with serious infections","peakSalesEstimate":"Not available"},"references":[],"biosimilars":[],"competitors":["Cefotaxime","Ceftazidime","Imipenem","Meropenem","Vancomycin"],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":["Lower respiratory tract infections","Urinary tract infections","Skin and soft tissue infections","Bacterial meningitis","Gonorrhea","Intra-abdominal infections"],"offLabel":["Bone and joint infections","Endocarditis","Septicemia"],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT01247909","phase":"PHASE4","title":"Infant Severe Sepsis and Bacterial Meningitis in Malawi","status":"COMPLETED","sponsor":"Kamuzu University of Health Sciences","startDate":"2010-04","conditions":"Infant Bacterial Meningitis","enrollment":351}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":["Teva Pharmaceuticals","Mylan Pharmaceuticals","Sandoz Inc.","Apotex Corp."],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Ceftriaxone v penicillin and gentamicin","genericName":"Ceftriaxone v penicillin and gentamicin","companyName":"Kamuzu University of Health Sciences","companyId":"kamuzu-university-of-health-sciences","modality":"Small molecule","firstApprovalDate":"Not available","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}